Disclaimer: Epilepsy Research UK is completely neutral and is not affiliated with any commercial company, or any particular device/product.
The medical company, MMJ PhytoTech Limited, has recently announced that it will begin a new phase two clinical trial by the end of this year to test the effectiveness of its new drug compound, PTL101, in treating children with drug-resistant epilepsy.
During the trial, PTL101 will be administered in the form of capsules containing organically-derived, highly purified cannabidiol – one of more than 100 active ‘cannabinoids’ identified in cannabis.
In a press release, Andreas Gedeon, Managing Director of MMJ PhytoTech said: “We are very pleased to be commencing the Phase 2 clinical trial of our PTL101 capsules, as it marks another critical milestone in the company’s evolution.”
The trial will take place at a centre in Israel and, at present, there has been no indication from the company as to whether it will extend to other sites
... read more at: https://www.epilepsyresearch.org.uk/18603-2/